Patheon NV (PTHN) Stake Maintained by Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
disclosed that they own a 99% stake in Patheon NV (NASDAQ:PTHN) in a Schedule 13D/A disclosure that was filed with the SEC on Wednesday, September 13th. The investor owns 143,781,162 shares of the stock worth $5,029,465,047. The reporting parties listed on the disclosure included Thermo Fisher Scientific Inc and Thermo Fisher (CN) Luxembourg Sà rl. The filing is available through Edgar at this link.
Thermo Fisher Scientific Inc.
provided the following explanation of their ownership:
This Amendment reports a change in the percentage of Purchaser and Parent’s beneficial ownership of the Shares of the Issuer since the filing of the Schedule 13D. The information set forth under Item 5 is incorporated herein by reference.
Other institutional investors and hedge funds have also modified their holdings of the company. Public Employees Retirement System of Ohio raised its holdings in Patheon NV by 273.1% in the second quarter. Public Employees Retirement System of Ohio now owns 41,916 shares of the company’s stock valued at $1,462,000 after acquiring an additional 30,680 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Patheon NV in the second quarter valued at approximately $2,013,000. CNH Partners LLC acquired a new stake in Patheon NV in the second quarter valued at approximately $46,539,000. BlueCrest Capital Management Ltd acquired a new stake in Patheon NV in the second quarter valued at approximately $1,172,000. Finally, Goldman Sachs Group Inc. raised its holdings in Patheon NV by 29.9% in the second quarter. Goldman Sachs Group Inc. now owns 130,327 shares of the company’s stock valued at $4,546,000 after acquiring an additional 30,034 shares in the last quarter.
Shares of Patheon NV (NASDAQ:PTHN) remained flat at $34.98 during midday trading on Wednesday. The company’s stock had a trading volume of 229,751 shares. The firm’s 50 day moving average price is $34.98 and its 200 day moving average price is $32.36. Patheon NV has a 52 week low of $24.45 and a 52 week high of $35.02. The stock has a market capitalization of $5.08 billion and a PE ratio of 44.85.
ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.watchlistnews.com/patheon-nv-pthn-stake-maintained-by-thermo-fisher-scientific-inc/1559804.html.
A number of analysts have weighed in on PTHN shares. Zacks Investment Research upgraded shares of Patheon NV from a “hold” rating to a “buy” rating and set a $39.00 target price on the stock in a research report on Friday, May 19th. Jefferies Group LLC restated a “hold” rating and set a $35.00 target price on shares of Patheon NV in a research report on Friday, July 21st. Raymond James Financial, Inc. restated a “market perform” rating and set a $35.00 target price on shares of Patheon NV in a research report on Thursday, June 8th. Leerink Swann lowered shares of Patheon NV from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $31.00 to $35.00 in a research report on Friday, June 9th. Finally, J P Morgan Chase & Co lowered shares of Patheon NV from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $34.50.
Patheon NV Profile
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
Want to see what other hedge funds are holding PTHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Patheon NV (NASDAQ:PTHN).
Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with Analyst Ratings Network's FREE daily email newsletter.